The Greenwood lab, in collaboration with the Abbott, Jepps and Rosenbaum labs and others, has discovered the molecular basis for arterial relaxation by SGLT2 inhibitors: these drugs relax mesenteric arteries by promoting the release of CGRP from sensory nerves in a NHE1-dependent manner. The work provides a crucial piece of evidence as to how these well-known hypoglycemic drugs also provide substantial cardiovascular benefits.
The work was published today in Cardiovascular Research.